Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Kidney Disease (CKD) Stage 3, 4, or 5 (not on dialysis), Glomerular Filtration Rate (GFR) \[\<60 mL/min/1.73 m2\], or CKD Stage 2 (GFR 61-90 mL/min/1.73 mm2) with evidence of kidney damage (defined as structural or functional abnormalities of the kidneys) for greater than 3 months~* Hb \<11 g/dL measured at screening and a stable creatinine over the last 3 months~* expected to stay in a Long Term Care (LTC) facility for at least six months~* not receiving erythropoietic agents within eight weeks prior to screening.~Exclusion Criteria:~* No significant hematological disease (including, but not limited to, myelodysplastic syndrome, hematological malignancy, hemolytic syndromes, hemoglobinopathy), or with a current diagnosis of anemia due to blood loss (e.g., hemolysis or gastrointestinal bleeding) or any cause of anemia other than CKD (e.g., hypothyroidism, HIV)~* No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months prior to screening (prior superficial thrombophlebitis is not an exclusion criterion), or a history of cerebrovascular accident (CVA), transient ischemic attack (TIA), Acute Coronary Syndrome (ACS), or other arterial thrombosis within 6 months before study entry. \[ACS includes Unstable Angina, Q wave Myocardial Infarction and non-Q wave Myocardial Infarction\]~* No uncontrolled or severe cardiovascular disease including uncontrolled hypertension (systolic BP \> 170 mm/Hg, or diastolic BP \> 100 mm/Hg), or congestive heart failure (New York Heart Association (NYHA) Class IV)~* No known solid tumor malignancy, receiving chemotherapy for cancer or having major surgery within one month prior to screening or expected during study participation~* No history of receiving a transplanted organ, or scheduled to receive an organ transplant during the course of the study, with the exception of a corneal transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin Alfa (Type: EXPERIMENTAL): None
- Group 2 (Type: OTHER): Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).

Based on this trial design, predict the completion outcome and termination type (if applicable).